In the present study, we have addressed this issue by silencing podocalyxin expression in the highly aggressive triple-negative basal-like human breast cancer cell line, MDA-MB-231, or overexpressing it in a well-differentiated, ER-positive and PgR-positive, luminal-like human breast cancer cell line, MCF7 [23]. This evidence concerns the gene PODXL and breast carcinoma.